Search | BIO

Home

Search

197 Results Found

#BIOCEO19: Navigating Payers’ Expectations for Value-Based Agreements

Value-based agreements are becoming increasingly important in the biopharmaceutical reimbursement space, particularly as new advanced therapeutic modalities and prospective cures for diseases which previously had no comparable treatments enter the market. Yet the departure from more traditional…

Market Outlook—Leveraging Market Corrections for M&A or IPOs

After a multi-year expansion of company formation and in biopharma valuations, 2018 was a year of heightened market volatility. Investors’ eagerness to support new modalities enabled more than 50 biotech IPOs, but with much less mature clinical development progress than traditionally demonstrated…

Meet Kallyope’s Nancy Thornberry, Fireside Chat Speaker at #BIOCEO19

Biotech startups come in all shapes, sizes and approaches but have one thing in common: the drive to develop technology that will address a high unmet need and improve patients’ lives. Nancy Thornberry, the current CEO of Kallyope Inc., didn’t always work for startups, but she has spent a…

Meet Synlogic’s Aoife Brennan, Fireside Chat Speaker at #BIOCEO19

Dr. Aoife Brennan has always faced challenges head-on. A trained endocrinologist, she could have remained in her native country, Ireland, and led a fulfilling life as a medical doctor. Instead she embarked on a journey that eventually led to her current position as CEO of Synlogic. Brennan will be…

Using Decision Science for Negotiations: Getting to Win-Win

New medicines often progress from idea to regulatory approval through collaborative licensing agreements or acquisition. Deal-making has become one of the most critical skills for a biotech’s leadership team in developing products to improve patients’ lives. On February 10 BIO will…

Investors lining up for BIO CEO & Investor Conference

The past year has been a transformative one for the life sciences. Despite being faced with uncertainties around cost and pricing, pressure from an Administration threatening price controls and facing a new Congress next year, the industry continued to move forward on the innovation front. With…

Researcher looking at substance underneath a microscope

Meet Opiant’s Roger Crystal, Fireside Chat Speaker at #BIOCEO19

When pop star Demi Lovato experienced an apparent opioid-related overdose last summer, reports stated that she was saved by a medication called NARCAN® Nasal Spray — the first FDA-approved nasal form of naloxone, an opioid antagonist. The company that developed NARCAN® Nasal Spray is Opiant…

Beyond Labels: 10 Things You Should Know About GMOs

As the new federal guidlines for disclosure of bioengineered foods (in the form of the National Bioengineered Food Disclosure Law) are expected to be announced soon, let's take a look at what you really need to know about genetically modified organisms, genetically modified crops, and genetically…

GMOs: Responding to the Issue of Food Waste and Loss

Food waste and food loss is a hot topic right now and rightly so. The United Nations has set a target of halving food loss and waste by 2030. But a new consulting group has found that if current trends continue, food waste will continue to rise, both in terms of volume and in terms of money lost. …

Will ECJ Ruling Be “The Deathblow for Plant Biotech in Europe”?

On July 25, when the European Court of Justice (ECJ), the European Union’s highest court, issued its strict legal ruling on directed mutagenesis, stakeholders and observers in the industry, academic, science and government arenas responded with a combination of disappointment, shock and confusion. …